IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 49.92

Change

+0.18 (+0.36)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-17 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.95 (-0.67%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.64%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.20 (+0.19%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+0.31 (+0.34%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.01 (+0.05%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.16 (+0.50%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.58 (+0.61%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.01 (+0.02%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.15 (+0.25%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.01 (+0.04%)

USD 8.55M

ETFs Containing IHF

MSSS Northern Lights Fund Trus.. 9.86 % 0.00 %

+0.14 (+0.50%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.02% 80% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.02% 80% B- 77% C+
Trailing 12 Months  
Capital Gain -2.94% 10% F 23% F
Dividend Return 0.80% 56% F 9% A-
Total Return -2.14% 14% F 19% F
Trailing 5 Years  
Capital Gain 21.15% 52% F 62% D
Dividend Return 5.06% 63% D 14% F
Total Return 26.20% 52% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 5.67% 57% F 53% F
Dividend Return 6.30% 62% D 47% F
Total Return 0.64% 63% D 17% F
Risk Return Profile  
Volatility (Standard Deviation) 21.72% 43% F 50% F
Risk Adjusted Return 29.02% 57% F 43% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.